| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.042 | 0.5 |
| mRNA | bafilomycin A1 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.5 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.037 | 0.5 |
| mRNA | KHS101 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.5 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | Gemcitabine | GDSC1000 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.5 |
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.5 |